搜索
 > 【IL-4 R alpha】重组蛋白信息

IL-4 R alpha信息

英文名称:Interleukin-4 receptor subunit alpha
中文名称:白细胞介素-4受体α亚基
靶点别称:IL-4R-alpha,Soluble IL-4 receptor subunit alpha,582J2.1,Soluble IL-4R-alpha,IL-4RA,IL4-BP,sIL4Ralpha/prot,CD124,Interleukin 4 Receptor,IL-4 Receptor Subunit Alpha,IL4RA,Interleukin-4 Receptor Subunit Alpha,Interleukin-4 Receptor Alpha Chain,IL4R Nirs Vari
上市药物数量:1
临床药物数量:5
最高研发阶段:批准上市

IL-4 R alpha 分子别名

IL4R,CD124,IL4RA

IL-4 R alpha 分子背景

IL-4 is a pleiotropic cytokine produced by activated Th2 cells and mast cells, and plays a pivotal role in immune responses. The effects of IL-4 are mediated after binding to high affinity receptor complexes present on hematopoietic as well as non-hematopoietic cells. Hematopoietic cellular responses to IL-4 are mediated by a high affinity receptor complex comprised of the 140 kDa IL4Rα (CD124)subunit and the 70 kDa common cytokine γc chain (CD132).Interleukin 4 Receptor (IL4R) also known as CD124, IL4Rα and BSF receptor, is a type I cytokine receptor produced by activated Th2 cells and mast cells, and plays an important role in Th2-­biased immune responses, alternative macrophage activation, mucosal immunity, allergic inflammation, tumor progression, and atherogenesis. A soluble form of the encoded IL4R protein can be produced by an alternate splice variant or by proteolysis of the membrane-bound protein, and this soluble form can inhibit IL4-mediated cell proliferation and IL5 upregulation by T-cells. IL4R can alternatively associate with IL­13Ra1 to form the type II receptor which is responsive to both IL­4 and IL­13. Interleukin-4 receptor has been shown to interact with SHC1.

IL-4 R alpha 参考文献

IL-4 R alpha上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Dupilumab 度普利尤单抗 SAR-231893; REGN-668 批准上市 赛诺菲, Regeneron Pharmaceuticals Inc Dupixent Mainland China 特应性皮炎 Sanofi-Aventis Group 2017-03-28 大疱性类天疱疮, 超敏反应, 特应性皮炎, 角结膜炎, 花生过敏, 速发型超敏反应, 慢性阻塞性肺疾病, 痒疹, 鼻窦炎, 荨麻疹, 变应性支气管肺曲霉菌病, 神经性皮炎, 哮喘, 过敏性鼻炎, 嗜酸性粒细胞性食管炎, 遗传病, 皮肤性疾病, 皮肤病,湿疹, 皮炎, 慢性荨麻疹 详情

IL-4 R alpha临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
AK120 (Akeso Biopharma) AK120 (Akeso Biopharma) 临床一期 中山康方生物医药有限公司 特应性皮炎 详情
Recombinant anti-IL-4Rα humanized monoclonal antibody (Sansheng Guojian) 611 临床一期 三生国健药业(上海)股份有限公司 特应性皮炎 详情
MG-K10 MG-K10; MG-010 临床一期 上海麦济生物技术有限公司, 宝船生物医药科技(上海)有限公司 哮喘 详情
QX-005N QX-005N 临床一期 江苏荃信生物医药有限公司 特应性皮炎 详情
SHR-1819 SHR-1819 临床一期 Atridia Pty Ltd 哮喘 详情
Recombinant humannized monoclonal antibody (Conmed Biosciences) CM-310 临床二期 康诺亚生物医药科技(成都)有限公司 鼻息肉, 鼻窦炎, 哮喘, 特应性皮炎 详情
Interleukin-4(38-37)-PE38KDEL MDNA-55; IL4-PE; NBI-3001; PRX-321 临床二期 Neurocrine Biosciences, National Institute of Health, Islamabad 肾肿瘤, 胶质母细胞瘤, 中枢神经系统肿瘤, 脑癌, 乳腺癌, 肺癌, 胶质瘤 详情
PRS-060 PRS-060; AZD-1402 临床二期 墨尔本大学, Pieris Pharmaceuticals 哮喘 详情
CBP-201 CBP-201 临床二期 苏州康乃德生物医药有限公司 鼻疾病, 哮喘, 特应性皮炎 详情

消息提示

请输入您的联系方式,再点击提交!

确定